Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial - Jastreboff, Ania M.; Kaplan, Lee M.; Frías, Juan P.; Wu, Qiwei; Du, Yu; Gurbuz, Sirel; Coskun, Tamer; Haupt, Axel; Milicevic, Zvonko; Hartman, Mark L. (The New England journal of medicine, 2023)
Keywords: Adult; Agonists; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Body Mass Index; Body weight; Clinical Medicine; Clinical Medicine General; Confidence intervals; Diabetes; Diet; Double-Blind Method; Drug therapy; Endocrinology; Female; Gastric Inhibitory Polypeptide - agonists; Gastroenterology; GIP protein; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - agonists; Heart rate; Humans; Injections, Subcutaneous; Male; Nutrition; Obesity; Obesity - complications; Obesity - drug therapy; Peptides; Placebos; Receptors, Glucagon - agonists; Statistical analysis; Treatment Outcome; Weight control; Weight Loss - drug effects; United States--US